HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Treatment of localized extranodal NK/T cell lymphoma, nasal type.

Abstract
Extranodal NK/T cell lymphoma predominantly presents as a localized disease in the upper aerodigestive tract from the nasal cavity to the hypopharynx. Because radiotherapy has better outcomes than chemotherapy with reduced locoregional failure, it should be considered the preferred first-line therapy. However, the addition of chemotherapy is appropriate as part of the initial treatment because of the frequent systemic progression or relapse after radiotherapy. At present, the combination of radiotherapy and chemotherapy can be considered an effective treatment option, and the promising results of recent prospective studies with concurrent chemoradiotherapy support this treatment strategy. In contrast, intensive chemotherapy should be considered as initial treatment for patients with tumors in non-upper-aerodigestive-tract sites, such as skin or intestine because they usually progress to systemic disease. Likewise, for patients with poor prognostic factors, such as a high NK lymphoma prognostic index, autologous stem cell transplantation during remission and additional treatments with central nervous system prophylaxis may be beneficial. However, the precise role of these treatments needs to be clarified further by prospective clinical trials. Thus, a prospective study is warranted to explore a risk-adapted treatment strategy of applying initial chemoradiotherapy and additional consolidation treatments.
AuthorsSeok Jin Kim, Won Seog Kim
JournalInternational journal of hematology (Int J Hematol) Vol. 92 Issue 5 Pg. 690-6 (Dec 2010) ISSN: 1865-3774 [Electronic] Japan
PMID21086194 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
Topics
  • Drug Therapy
  • Humans
  • Lymphoma, Extranodal NK-T-Cell (therapy)
  • Neoplasms, Second Primary (prevention & control)
  • Radiotherapy
  • Salvage Therapy
  • Stem Cell Transplantation
  • Transplantation, Autologous
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: